Congenital anomalies contribute significantly to the burden of human disease; Baird et al' have estimated their birth incidence to be over 5%. Their aetiology may be chromosomal, single gene, environmental, polygenic, multifactorial, or unknown. The final three categories comprise the majority, and very few "polygenes" have yet been implicated in congenital malformations (the association of cleft lip ± palate with genetic variation at the transforming growth factor-alpha locus in 2p13 is one exception).2' However, considerable progress has been made in the identification of chromosomal, single gene, and environmental contributions to malformation: this article summarises current (March 1994 ) knowledge about those disorders that have been mapped in the human genome. Detailed information on each disorder is provided in table 1, arranged in chromosomal order: the nomenclature used has recently been explained in this Journal.4 Table 2 presents an alphabetical list of these disorders for ease of reference, and the figure shows their localisation on the human genome map. Appropriate references may be found in McKusick's catalogue,5 together with various reviews.69 Cita- tions in this article are selective and refer to recent or particularly pertinent work.
In compiling this gene map we had some difficulty in deciding which particular disorders qualified as "congenital malformations". Spranger et al'0 defined a malformation as "a morphologic defect of an organ, part of an organ, or larger region of the body resulting from an intrinsically abnormal developmental process". The suggested distinction from dysplasia ("an abnormal organisation of cells into tissue(s) and its morphologic result(s)")'0 is difficult to make in practice. Here Over the next few years, integration of the flood of information generated by the Human Genome Project with the characterisation of important developmental genes in Drosophila, mice, and other organisms will greatly increase the power of the "positional candidate" approach8 to identify the molecular basis of malformation. Increasingly, initial chromosomal localisation of rare disorders may 27 Conversely, a diverse range of distinct phenotypes can arise from different mutations of a single gene. This is particularly well illustrated by the type 2 collagen gene COL2A1. Diseases in which mutations of this gene have been described include Stickler and Wagner syndromes, spondyloepiphyseal dysplasia congenita, Kniest dysplasia, achondrogenesis, and precocious osteoarthritis. The phenotype presumably depends on the precise mutation and, in at least one case, its presence only in mosaic form. 28 Several genes have been implicated in both congenital malformation and neoplasia, the phenotype depending on the timing (germline or somatic) and/or precise nature of the mutation. Such combined "teratogenes"/oncogenes (or tumour suppressor genes) include PAX3 (Waardenburg syndrome/alveolar rhabdomyosarcoma), RET (Hirschsprung disease, multiple endocrine neoplasia type 2B/medullary thyroid carcinoma29), and WT1 (DenysDrash syndrome/Wilms tumour), illustrating that similar developmental pathways control cellular growth and differentiation in the embryo and adult.
In a small number of cases the characteristic phenotype may arise from the deletion or duplication of two or more closely adjacent genes. Examples of such "contiguous gene syndromes"30 include the WAGR complex in llpl3, the occurrence of type II oculocutaneous albinism in some cases of Prader-Willi and Angelman syndromes,3' and, probably, the association of supravalvular aortic stenosis with mental retardation and characteristic behavioural changes in Williams syndrome.2'
The identification of disease loci and genes in congenital malformations may have a number of practical benefits. It enables more specific diagnosis, prognosis, carrier testing, and prenatal prediction. In some of the recessive metabolic diseases, it paves the way for possible gene therapy, although most congenital malformations are unlikely to benefit from this approach. Particularly important in the diagnostic context is the discovery that certain regions of the genome (notably 15ql1-ql3, l7pl1.2, and 22ql 132) seem especially prone to deletions. 
